90
Participants
Start Date
November 17, 2021
Primary Completion Date
August 31, 2026
Study Completion Date
November 15, 2026
TORL-1-23
antibody drug conjugate (ADC)
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
St. Vincent's Hospital, The Catholic University of Korea, Suwon
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
University of Kentucky Medical Center, Lexington
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Mayo Clinic in Rochester, Rochester
RECRUITING
Sarah Cannon Research Institute Texas Oncology, Tyler
RECRUITING
UCLA - JCCC Clinical Research Unit, Los Angeles
RECRUITING
Providence Medical Foundation, Fullerton
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
Translational Research in Oncology
OTHER
TORL Biotherapeutics, LLC
INDUSTRY